We claim:

1. An immunogenic composition comprising 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates and a protein component comprising PilA or an immunogenic fragment of PilA from *Haemophilus influenzae*.

2. An immunogenic composition comprising 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates and a protein component comprising PilA from *Haemophilus influenzae*.

3. The immunogenic composition of claim 1 wherein the protein component comprises Protein E or an immunogenic fragment of Protein E and PilA or an immunogenic fragment of PilA from *Haemophilus influenzae*.

4. The immunogenic composition of claim 2 wherein the protein component comprises Protein E and PilA from *Haemophilus influenzae*.

5. The immunogenic composition of claim 3 or 4 wherein Protein E is a polypeptide of SEQ ID NO: 4.

6. The immunogenic composition of any one of claims 3-5 wherein Protein E or the immunogenic fragment of Protein E is a polypeptide comprising a sequence having at least 75%, 77%, 80%, 85%, 90%, 95%, 97%, 99% or 100% identity over the entire length, to SEQ ID NO. 4.

7. The immunogenic composition of claim 3, 4 or 6 wherein the immunogenic fragment of Protein E is a polypeptide comprising an immunogenic fragment of at least 7, 10, 15, 20, 25, 30,50, 75 or 100 contiguous amino acids of SEQ ID NO. 4.

8. The immunogenic composition of claim 7 wherein the immunogenic fragment of SEQ ID NO:4 comprises a B and/or T cell epitope of SEQ ID NO: 4.

9. The immunogenic composition of any one of claims 3-8 wherein Protein E or the immunogenic fragment of protein E is capable of eliciting an immune response which recognizes SEQ ID NO. 4.

10. The immunogenic composition of any preceding claim wherein PilA is a polypeptide of SEQ ID NO. 58.

11. The immunogenic composition of any one of claims 1-9 wherein PilA or the immunogenic fragment of PilA is a polypeptide comprising a sequence having at least 80%, 85%, 90%, 95%, 97% or 100% identity, over the entire length, to SEQ ID NO. 58.

AMENDED SHEET

12. The immunogenic composition of any one of claims 1-9 or 11 wherein PilA or the immunogenic fragment of PilA is a polypeptide comprising an immunogenic fragment of at least 7, 10, 15, 20, 25, 30 or 50 contiguous amino acids of SEQ ID NO. 58.

13. The immunogenic composition of claim 12, wherein the immunogenic fragment of SEQ ID NO:58 comprises a B and/or T cell epitope of SEQ ID NO: 58.

14. The immunogenic composition of any preceding claim wherein PilA or the immunogenic fragment of PilA is capable of eliciting an immune response which recognizes SEQ ID NO. 58.

15. The immunogenic composition of any preceding claim comprising Protein E or an immunogenic fragment of protein E covalently linked to PilA or an immunogenic fragment of PilA to form a fusion protein.

16. The immunogenic composition of claim 15 wherein the fusion protein has formula I:

(X) m – (R1)n – A – (Y) o – B – (Z)p (formula I)

wherein:

X is a signal peptide or MHHHHHH (SEQ ID NO. 2);
m is 0 or 1;
R1 is an amino acid;
n is 0, 1, 2, 3, 4, 5 or 6;
A is Protein E from *Haemophilus influenzae* or an immunogenic fragment thereof, or PilA from *Haemophilus influenzae* or an immunogenic fragment thereof;
Y is selected from the group consisting of GG, SG, SS, GGG and (G)h wherein h is 4, 5, 6, 7, 8, 9, or 10;
o is 0 or 1;
B is PilA from *Haemophilus influenzae* or an immunogenic fragment thereof, or Protein E from *Haemophilus influenzae* or an immunogenic fragment thereof;
Z is GGHHHHHH (SEQ ID NO. 3); and
p is 0 or 1.

17. The immunogenic composition of claim 16 wherein X is selected from the group consisting of FlgI, NadA and PelB.

18. The immunogenic composition of claim 16 or 17 wherein m is 0.

19. The immunogenic composition of any one of claims 16-18 wherein n is 0.

AMENDED SHEET

20. The immunogenic composition of any one of claims 16-19 wherein A is an immunogenic fragment of Protein E, wherein Protein E is selected from any one of SEQ ID NO. 4 – SEQ ID NO. 57.

21. The immunogenic composition of any one of claims 16-20 wherein A is the immunogenic fragment of Protein E from *H. influenzae* as set forth in SEQ ID NO: 124.

22. The immunogenic composition of any one of claims 16-21 wherein Y is GG.

23. The immunogenic composition of any one of claims 16-22 wherein B is an immunogenic fragment of PilA, wherein PilA is selected from any one of SEQ ID NO. 58 – SEQ ID NO. 121.

24. The immunogenic composition of any one of claims 16-23 wherein B is the immunogenic fragment of PilA from *H. influenzae* as set forth in SEQ ID NO 127.

25. The immunogenic composition of any one of claims 16-24 wherein the fusion protein is selected from the group consisting of SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO.182, SEQ ID NO.184, SEQ ID NO.186, SEQ ID NO.188, SEQ ID NO. 190, SEQ ID NO.192, SEQ ID NO.194, SEQ ID NO.196, SEQ ID NO.198, SEQ ID NO.200, SEQ ID NO.202 and SEQ ID NO.204.

26. The immunogenic composition of any one of claims 16-25 wherein the fusion protein is at least 95%, 98% or 99% identical to any of SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202 or SEQ ID NO. 204.

27. The immunogenic composition of any one of claims 16-26 wherein the signal peptide has been removed.

28. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 1 saccharide.

29. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 4 saccharide.

AMENDED SHEET

30. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 5 saccharide.

31. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 6B saccharide.

32. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 7F saccharide.

33. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 9V saccharide.

34. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 14 saccharide.

35. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 18C saccharide.

36. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 19F saccharide.

37. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 23F saccharide.

38. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 3 saccharide.

39. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 6A saccharide.

40. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 19A saccharide.

AMENDED SHEET

41. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 33F saccharide.

42. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 22F saccharide.

43. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates are conjugated to a carrier protein independently selected from the group consisting of tetanus toxoid (TT), fragment C of TT, diphtheria toxoid, CRM197 (cross reacting material 197), Pneumolysin, protein D (from *H.influenzae*), PhtD (Poly Histidine Triad D), PhtDE ( a fusion between Pneumococal Histidine Triad D and E) and N19.

44. The immunogenic composition of any preceding claim wherein the *Streptococcus pneumoniae* capsular saccharide conjugates are all independently conjugated to CRM197.

45. The immunogenic composition of claim 28 wherein the conjugated serotype 1 saccharide is conjugated to protein D or CRM197.

46. The immunogenic composition of claim 29 wherein the conjugated serotype 4 saccharide is conjugated to protein D or CRM197.

47. The immunogenic composition of claim 30 wherein the conjugated serotype 5 saccharide is conjugated to protein D or CRM197.

48. The immunogenic composition of claim 31 wherein the conjugated serotype 6B saccharide is conjugated to protein D or CRM197.

49. The immunogenic composition of claim 32 wherein the conjugated serotype 7F saccharide is conjugated to protein D or CRM197.

50. The immunogenic composition of claim 33 wherein the conjugated serotype 9V saccharide is conjugated to protein D or CRM197.

51. The immunogenic composition of claim 34 wherein the conjugated serotype 14 saccharide is conjugated to protein D or CRM197.

52. The immunogenic composition of claim 35 wherein the conjugated serotype 18C saccharide is conjugated to tetanus toxoid or CRM197.

53. The immunogenic composition of claim 36 wherein the conjugated 19F saccharide is conjugated to diphtheria toxoid or CRM197.

54. The immunogenic composition of claim 37 wherein the conjugated 23F saccharide is conjugated to protein D or CRM197.

55. The immunogenic composition of claim 39 wherein the conjugated 6A saccharide is conjugated to CRM197.

56. The immunogenic composition of claim 40 wherein the conjugated 19A saccharide is conjugated to CRM197.

57. The immunogenic composition of claim 38 wherein the conjugated 3 saccharide is conjugated to CRM197.

58. The immunogenic composition of claim 41 wherein the conjugated 33F saccharide is conjugated to CRM197.

59. The immunogenic composition of claim 42 wherein the conjugated 22F saccharide is conjugated to CRM197.

60. The immunogenic composition of any preceding claim wherein a minority of the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates are conjugated to protein D.

61. The immunogenic composition of any one of claims 1-43 or 45-56 wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a serotype 1 saccharide conjugated to protein D, a serotype 4 saccharide conjugated to protein D, a serotype 5 saccharide conjugated to protein D, a serotype 6B saccharide conjugated to protein D, a serotype 7F saccharide conjugated to protein D, a serotype 9V saccharide conjugated to protein D, a serotype 14 saccharide conjugated to protein D, a serotype 14 saccharide conjugated to protein D, a serotype 23F saccharide conjugated to protein D, a serotype 18C saccharide conjugated to tetanus toxoid and a serotype 19F saccharide conjugated to diphtheria toxoid.

62. The immunogenic composition of claim 61 further comprising a serotype 6A saccharide conjugated to CRM197 and a serotype 19A saccharide conjugated to CRM197.

63. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 saccharides conjugated to a carrier protein through reductive amination.

64. The immunogenic composition of any preceding claim wherein all of the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates are conjugated to a carrier protein through reductive amination.

65. The immunogenic composition of any one of claims 1-63 wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 saccharides conjugated to a carrier protein through CDAP chemistry.

66. The immunogenic composition of any one of claims 1-62 or 65 wherein all of the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates are conjugated to a carrier protein through CDAP chemistry.

67. The immunogenic composition of any one of claims 1-63 or 65 wherein 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 saccharides conjugated to a carrier protein through reductive amination and comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 saccharides conjugated to a carrier protein through a chemistry other than reductive amination for example CDAP chemistry.

68. The immunogenic composition of any preceding claim wherein the dose of the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates is between 1 and 10µg, 1 and 5µg, or 1 and 3µg of saccharide per conjugate.

69. The immunogenic composition of any preceding claim wherein 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises conjugates of saccharides from serotypes 1, 5, 6B, 7F, 9V, 14 and 23F (and optionally 6A and/or 3) at dosages of 1µg of saccharide per conjugate.

70. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises conjugates of saccharides from serotypes 4, 18C, and 19F(and optionally 22F and/or 19A) at dosages of 3µg of saccharide per conjugate.

71. The immunogenic composition of any preceding claim wherein the immunogenic composition comprises less than 23, 22, 21, 20, 19, 18, 17, 16, 15, 14 or 13 *Streptococcus pneumoniae* capsular saccharide conjugates.

72. The immunogenic composition of any preceding claim wherein the immunogenic composition further comprises unconjugated *Streptoococcus pneumoniae* saccharides of serotypes different from those conjugated, such that the number of conjugated and unconjugated saccharide serotypes is less than or equal to 23.

AMENDED SHEET

73. The immunogenic composition of any preceding claim wherein the immunogenic composition further comprises at least one unconjugated or conjugated *Streptococcus pneumoniae* protein.

74. The immunogenic composition of claim 73 wherein the at least one unconjugated or conjugated *Streptococcus pneumoniae* protein is selected from the group consisting of Poly Histidine Triad family (PhtX), detoxified pneumolysin (dPly), Choline Binding Protein Family (CbpX), CbpX truncates, LytX (autolytic enzymes) family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, PcpA (Pneumococcal Choline Binding Protein A), PspA (Pneumococcal Surface Protein A), PsaA (Pneumococcal Surface Adhesin A), Sp128 (*Streptococcus pneumoniae* 128), Sp101(*Streptococcus pneumoniae* 101), Sp130(*Streptococcus pneumoniae* 130), SP125(*Streptococcus pneumoniae* 125) and SP133(*Streptococcus pneumoniae* 133).

75. The immunogenic composition of claim 73 wherein the at least one unconjugated or conjugated *Streptococcus pneumoniae* protein comprises a Poly Histidine Triad family (PhtX) protein selected from the group consisting of PhtD, PhtB and PhtA.

76. The immunogenic composition of any one of claims 73-75 wherein the at least one unconjugated or conjugated *Streptococcus pneumoniae* protein is a PhtD protein.

77. The immunogenic composition of claim 76 wherein the PhtD protein comprises an amino acid sequence at least 85%, 90%, 95%, 98%, 99% or 100% identical to SEQ ID NO:220.

78. The immunogenic composition of any one of claims 73-74 wherein the at least one unconjugated or conjugated *Streptococcus pneumoniae* protein is detoxified pneumolysin (dPly).

79. The immunogenic composition of claim 78 wherein the pneumolysin has been chemically detoxified.

80. The immunogenic composition of claim 78 or 79 wherein the pneumolysin has been genetically detoxified.

81. The immunogenic composition of any one of claims 73-80 wherein the immunogenic composition comprises unconjugated PhtD and unconjugated pneumolysin.

82. The immunogenic composition of any preceding claim which further comprises an adjuvant.

AMENDED SHEET

83. The immunogenic composition of claim 82 wherein the adjuvant is aluminium phosphate.

84. The immunogenic composition of claim 83 wherein the adjuvant comprises 100-750, 200-500, or 300-400µg Al as aluminium phosphate per human dose.

85. A vaccine comprising the immunogenic composition of any preceding claim and a pharmaceutically acceptable excipient.

86. A method of immunising a subject against diseases caused by *Streptococcus pneumoniae* infection comprising administering to the subject a therapeutically effective dose of the immunogenic composition of any one of claims 1-84 or the vaccine of claim 85.

87. A method of immunising a subject against diseases caused by *Haemophilus influenzae* infection comprising administering to the subject a therapeutically effective dose of dose of the immunogenic composition of any one of claims 1-84 or the vaccine of claim 85.

88. The method of claim 86 or 87 wherein the subject is a mammalian subject.

89. The method of claim 88 wherein the mammalian subject is selected from a mouse, a guinea pig, and a human.

90. The method of any one of claims 86-89 wherein the subject is an adult human.

91. The method of any one of claims 86-89 wherein the subject is an elderly human.

95. The method of claim 86-89 wherein the subject is an infant human.

93. The method of any one of claims 86-93 wherein the diseases comprise at least one disease selected from the group consisting of pneumonia, invasive pneumococcal disease (IPD), exacerbations of chronic obstructive pulmonary disease (COPD), otitis media, meningitis, bacteraemia, and conjunctivitis.

94. An immunogenic composition according to any one of claims 1-84 or a vaccine according to claim 85 for use in the treatment or prevention of diseases caused by *Streptococcus pneumoniae* infection.

95. An immunogenic composition according to any one of claims 1-84 or a vaccine according to claim 85 for use in the treatment or prevention of diseases caused by *Haemophilus influenzae* infection.

96. The immunogenic composition of claim 94 or 95 wherein the use comprises administration of the immunogenic composition to an adult human host.

AMENDED SHEET

97. The immunogenic composition of any one of claims 94-95 wherein the use comprises administration of the immunogenic composition to an elderly human host.

98. The immunogenic composition of claim 94 or 95 wherein the use comprises administration of the immunogenic composition to an infant human host.

99. The immunogenic composition of any one of claims 94-98 wherein the diseases comprise at least one disease selected from the group consisting of pneumonia, invasive pneumococcal disease (IPD), exacerbations of chronic obstructive pulmonary disease (COPD), otitis media, meningitis, bacteraemia, and conjunctivitis.

100. A use of the immunogenic composition of any one of claims 1-84 or the vaccine of claim 85 in the manufacture of a medicament for the treatment or prevention of diseases caused by *Streptococcus pneumoniae* infection.

101. A use of the immunogenic composition of any one of claims 1-84 or the vaccine of claim 85 in the manufacture of a medicament for the treatment or prevention of diseases caused by *Haemophilus influenzae* infection.

102. The use of claim 100 or 101 comprising administration of the immunogenic composition of any one of claims 1-85 or the vaccine of claim 74 to a host selected from the group consisting of an adult human host, an elderly human host and an infant human host.

103. The use of any one of claims 100-102 wherein the diseases comprise at least one disease selected from the group consisting of pneumonia, invasive pneumococcal disease (IPD), exacerbations of chronic obstructive pulmonary disease (COPD), otitis media, meningitis, bacteraemia, and conjunctivitis.

We claim:

1. An immunogenic composition comprising 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates and a protein component comprising PilA or an immunogenic fragment of PilA from *Haemophilus influenzae*.

2. An immunogenic composition comprising 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates and a protein component comprising PilA from *Haemophilus influenzae*.

3. The immunogenic composition of claim 1 wherein the protein component comprises Protein E or an immunogenic fragment of Protein E and PilA or an immunogenic fragment of PilA from *Haemophilus influenzae*.

4. The immunogenic composition of claim 2 wherein the protein component comprises Protein E and PilA from *Haemophilus influenzae*.

5. The immunogenic composition of any one of claims 3-4 wherein Protein E or the immunogenic fragment of Protein E is a polypeptide comprising a sequence having at least 75%, 77%, 80%, 85%, 90%, 95%, 97%, 99% or 100% identity, over the entire length, to SEQ ID NO. 4.

6. The immunogenic composition of claim 3, 4 or 5 wherein the immunogenic fragment of Protein E is a polypeptide comprising an immunogenic fragment of at least 7, 10, 15, 20, 25, 30, 50, 75 or 100 contiguous amino acids of SEQ ID NO. 4.

7. The immunogenic composition of any one of claims 1-6 wherein PilA or the immunogenic fragment of PilA is a polypeptide comprising a sequence having at least 80%, 85%, 90%, 95%, 97% or 100% identity, over the entire length, to SEQ ID NO. 58.

8. The immunogenic composition of any one of claims 1-7 wherein PilA or the immunogenic fragment of PilA is a polypeptide comprising an immunogenic fragment of at least 7, 10, 15, 20, 25, 30 or 50 contiguous amino acids of SEQ ID NO. 58.

9. The immunogenic composition of any preceding claim comprising Protein E or an immunogenic fragment of protein E covalently linked to PilA or an immunogenic fragment of PilA to form a fusion protein.

10. The immunogenic composition of claim 9 wherein the fusion protein has formula I:

(X) m – (R1)n – A – (Y) o – B – (Z)p (formula I)

wherein:

X is a signal peptide or MHHHHHH (SEQ ID NO. 2);

m is 0;

R1 is an amino acid;

n is 0;

o is 0 or 1;

Z is GGHHHHHH (SEQ ID NO. 3);

p is 0 or 1;

A is an immunogenic fragment of Protein E, wherein Protein E is selected from any one of SEQ ID NO. 4 – SEQ ID NO. 57;

Y is GG;

and B is an immunogenic fragment of PilA, wherein PilA is selected from any one of SEQ ID NO. 58 – SEQ ID NO. 121.

11. The immunogenic composition of claim 9 or 10 wherein the fusion protein is SEQ ID NO.194.

12. The immunogenic composition of any one of claims 9-10 wherein the fusion protein is at least 95%, 98% or 99% identical to any of SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202 or SEQ ID NO. 204.

13. The immunogenic composition of any one of claims 9-12 wherein the signal peptide has been removed.

14. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a conjugated serotype 1 saccharide, a conjugated serotype 4 saccharide, a conjugated serotype 5 saccharide, a conjugated serotype 6B saccharide, a conjugated serotype 7F saccharide,a conjugated serotype 9V saccharide, a conjugated serotype 14 saccharide, a conjugated serotype 18C saccharide, a conjugated serotype 19F saccharide and a conjugated serotype 23F saccharide.

15. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates further comprises a conjugated serotype 6A saccharide and a conjugated serotype 19A saccharide.

16. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates further comprises a conjugated serotype 33F saccharide and a conjugated serotype 22F saccharide.

17. The immunogenic composition of any preceding claim wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates are conjugated to a carrier protein independently selected from the group consisting of tetanus toxoid (TT), fragment C of TT, diphtheria toxoid, CRM197 (cross reacting material 197), Pneumolysin, protein D (from *H.influenzae*), PhtD (Poly Histidine Triad D), PhtDE ( a fusion between Pneumococal Histidine Triad D and E) and N19.

18. The immunogenic composition of any one of claims 1-17 wherein the 1 or more *Streptococcus pneumoniae* capsular saccharide conjugates comprises a serotype 1 saccharide conjugated to protein D, a serotype 4 saccharide conjugated to protein D, a serotype 5 saccharide conjugated to protein D, a serotype 6B saccharide conjugated to protein D, a serotype 7F saccharide conjugated to protein D, a serotype 9V saccharide conjugated to protein D, a serotype 14 saccharide conjugated to protein D, a serotype 14 saccharide conjugated to protein D, a serotype 23F saccharide conjugated to protein D, a serotype 18C saccharide conjugated to tetanus toxoid and a serotype 19F saccharide conjugated to diphtheria toxoid.

19. The immunogenic composition of any preceding claim wherein the immunogenic composition further comprises at least one unconjugated or conjugated *Streptococcus pneumoniae* protein selected from the group consisting of Poly Histidine Triad family (PhtX), detoxified pneumolysin (dPly), Choline Binding Protein Family (CbpX), CbpX truncates, LytX (autolytic enzymes) family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, PcpA (Pneumococcal Choline Binding Protein A), PspA (Pneumococcal Surface Protein A), PsaA (Pneumococcal Surface Adhesin A), Sp128 (*Streptococcus pneumoniae* 128), Sp101(*Streptococcus pneumoniae* 101), Sp130(*Streptococcus pneumoniae* 130), SP125(*Streptococcus pneumoniae* 125) and SP133(*Streptococcus pneumoniae* 133).

20. A vaccine comprising the immunogenic composition of any preceding claim and a pharmaceutically acceptable excipient.

21. An immunogenic composition according to any one of claims 1-19 or a vaccine according to claim 20 for use in the treatment or prevention of diseases caused by *Streptococcus pneumoniae* infection or an *Haemophilus influenzae* infection, wherein the diseases comprise at least one disease selected from the group consisting of

pneumonia, invasive pneumococcal disease (IPD), exacerbations of chronic obstructive pulmonary disease (COPD), otitis media, meningitis, bacteraemia, and conjunctivitis.

22. A use of the immunogenic composition of any one of claims 1-19 or the vaccine of claim 20 in the manufacture of a medicament for the treatment or prevention of diseases caused by *Streptococcus pneumonia* infection.

23. A use of the immunogenic composition of any one of claims 1-19 or the vaccine of claim 20 in the manufacture of a medicament for the treatment or prevention of diseases caused by *Haemophilus influenza* infection.

24. The use of claim 22 or 23 comprising administration of the immunogenic composition of any one of claims 1-20 or the vaccine of claim 20 to a host selected from the group consisting of an adult human host, an elderly human host and an infant human host.

25. The use of any one of claims 22-24 wherein the diseases comprise at least one disease selected from the group consisting of pneumonia, invasive pneumococcal disease (IPD), exacerbations of chronic obstructive pulmonary disease (COPD), otitis media, meningitis, bacteraemia, and conjunctivitis.